Group 1: Innovation in Medical Technology - Innovation Medical (002173) has established itself in the medical service sector, focusing on brain-computer interface (BCI) technology for clinical applications, particularly in neuro-rehabilitation and cardiovascular treatment [1][20] - The company's BCI-4000 product is in Phase III clinical trials, utilizing invasive electrodes to collect brain signals for device control, aiding rehabilitation for high-level paraplegics [1][20] - With the implementation of insurance reimbursement policies for BCI, the clinical transition process is expected to accelerate, potentially leading to significant growth in the neuro-rehabilitation business [1][20] Group 2: Digital Entertainment and AI Integration - Talking Tom (300459) leverages its popular IPs in digital entertainment and is actively exploring the integration of AI with brain-computer interfaces to create immersive interactive experiences [2][21] - The core business includes IP operation, mobile app development, and digital content creation, focusing on leisure and children's education [2][21] - The company aims to develop brain-controlled games and immersive entertainment applications, enhancing user engagement and monetization capabilities [2][21] Group 3: Precision Components in Medical Devices - Meihua Medical (301363) specializes in manufacturing precision medical components, providing essential support to global medical device companies, and has recently entered the brain-computer interface supply chain [3][22] - The company produces components for cardiovascular and neuro-interventional devices, including precision structural parts for BCI equipment [3][22] - As demand for BCI devices increases, the company anticipates a steady growth in orders for precision components, enhancing collaboration with BCI firms [3][22] Group 4: AI and Brain-Computer Interface Algorithms - Yanshan Technology (002195) focuses on brain-like intelligence and AI, with a strong emphasis on developing neural signal decoding algorithms for brain-computer interfaces [4][23] - The company aims to optimize brain signal decoding efficiency through AI algorithms, enhancing the precision control capabilities of BCI devices [4][23] - As the demand for algorithm precision in BCI increases, the company expects growth in algorithm licensing and system integration services [4][23] Group 5: Network Solutions for Brain-Computer Interfaces - StarNet Ruijie (002396) is a leading provider of network equipment and solutions, exploring network support solutions for brain-computer interface applications [5][25] - The company offers high-speed data transmission and processing solutions for BCI devices, facilitating real-time brain signal transmission and cloud analysis [5][25] - With the rising demand for data transmission efficiency in BCI, the company anticipates continued growth in high-speed network equipment demand [5][25] Group 6: Pain Management and Neuroregulation - Aipeng Medical (300753) specializes in pain management and neuroregulation, exploring the application of brain-computer interfaces in postoperative pain relief and neuro-rehabilitation [6][26] - The company focuses on developing devices for pain management and neuroregulation, aiming to enhance treatment efficiency through brain-computer technology [6][26] - As the demand for neuro-rehabilitation grows, the application of BCI in medical settings is expected to accelerate [6][26] Group 7: Security and Identity Verification - Entropy Technology (301330) leverages biometric recognition and identity verification technologies, applying brain-computer interfaces in security and identity authentication [7][27] - The company provides solutions for financial, governmental, and transportation sectors, focusing on the development of BCI applications for secure interactions [7][27] - As the demand for precision and security in identity verification increases, the potential for BCI applications in security will gradually be realized [7][27] Group 8: Smart Control Components and IoT Solutions - Yingqu Technology (002925) specializes in smart control components and IoT solutions, providing essential support for brain-computer interface devices [8][28] - The company serves consumer electronics and smart home sectors, offering smart control components that facilitate intelligent interaction and data collection for BCI devices [8][28] - With the rising demand for intelligent BCI devices, the company expects a continuous increase in orders for smart control components [8][28] Group 9: Precious Metal Materials for BCI Electrodes - Guiyan Platinum (600459) focuses on the research and production of precious metal materials, providing critical materials for brain-computer interface electrodes [9][29] - The company supplies platinum-based alloy materials that enhance the biocompatibility and signal stability of BCI electrodes [9][29] - As the demand for mass production of BCI electrodes increases, the company anticipates a steady growth in orders for precious metal materials [9][29] Group 10: Automotive Applications of Brain-Computer Interfaces - Yachuang Electronics (301099) is exploring the application of brain-computer interfaces in smart driving, focusing on automotive-grade chips and power semiconductors [10][30] - The company aims to implement brain control technology for vehicle operation, opening new possibilities in automotive intelligence [10][30] - As the demand for human-machine interaction in smart driving increases, the potential for BCI applications in the automotive sector will gradually be realized [10][30] Group 11: Industrial Applications of Brain-Computer Interfaces - Zhongke Information (300678) focuses on intelligent monitoring and industrial detection, applying brain-computer interfaces in industrial settings [11][31] - The company aims to utilize brain signals for equipment status monitoring and fault prediction, enhancing industrial efficiency [11][31] - As the demand for monitoring precision in industrial automation increases, the application of BCI in industrial settings is expected to accelerate [11][31] Group 12: Third-Party Testing for BCI Compliance - Puni Testing (300887) is a leading third-party testing organization, providing compliance testing services for brain-computer interface devices [12][32] - The company offers testing for biocompatibility and electromagnetic compatibility, ensuring the safety and compliance of BCI products [12][32] - As the BCI industry matures, the demand for compliance testing services is expected to grow, supporting the healthy development of the industry [12][32] Group 13: Flexible Materials for BCI Devices - Pulit (002324) specializes in the research and production of polymer materials, providing essential flexible packaging materials for brain-computer interface devices [13][33] - The company enhances the durability and biocompatibility of BCI devices through its flexible packaging solutions [13][33] - As the demand for flexible materials in BCI devices increases, the company anticipates a steady growth in orders for packaging materials [13][33] Group 14: Intelligent Equipment and Robotics - Tianqi Co., Ltd. (002009) focuses on intelligent equipment manufacturing and industrial automation, exploring the application of brain-computer interfaces in industrial robotics [14][34] - The company aims to implement brain control technology for precise robotic operation, enhancing manufacturing efficiency [14][34] - As the demand for precision in industrial automation increases, the application of BCI in robotics is expected to accelerate [14][34] Group 15: Medical Rehabilitation and Training - Chengyitong (300430) specializes in pharmaceutical intelligent manufacturing and rehabilitation equipment, exploring the application of brain-computer interfaces in rehabilitation training [15][35] - The company focuses on optimizing rehabilitation plans through brain control technology, enhancing training efficiency [15][35] - As the demand for neuro-rehabilitation grows, the application of BCI in medical settings is expected to accelerate [15][35] Group 16: Military Communication and Navigation - Haige Communication (002465) is a core enterprise in military communication and navigation, providing specialized support for brain-computer interfaces [16][36] - The company offers military communication and data transmission solutions for BCI devices, enhancing interaction in specialized scenarios [16][36] - As the demand for BCI in military applications increases, the need for communication equipment is expected to grow [16][36] Group 17: Smart Terminals and Information Systems - Nanjing Panda (600775) leverages electronic manufacturing and communication technology, exploring the application of brain-computer interfaces in smart terminals [17][37] - The company aims to implement brain control technology for device operation, opening new possibilities in consumer electronics [17][37] - As the demand for interactive methods in smart terminals increases, the potential for BCI applications in consumer electronics will gradually be realized [17][37] Group 18: Biocompatible Coatings for BCI Devices - Taihe Technology (300801) specializes in fine chemicals and water treatment materials, providing essential biocompatible coating materials for brain-computer interface devices [18][38] - The company enhances the safety and durability of BCI devices through its biocompatible coatings [18][38] - As the demand for biocompatibility in BCI devices increases, the company anticipates a steady growth in orders for coating materials [18][38] Group 19: Cardiovascular and Neurointerventional Applications - Lepu Medical (300003) focuses on cardiovascular and neurointerventional fields, exploring the application of brain-computer interfaces in cardiac rehabilitation and neuroregulation [19][39] - The company aims to optimize treatment plans through brain control technology, enhancing rehabilitation efficiency [19][39] - As the demand for cardiovascular and neuro-rehabilitation grows, the application of BCI in medical settings is expected to accelerate [19][39] Group 20: Intelligent Nursing and Patient Monitoring - Yahua Electronics (301337) specializes in medical information systems and intelligent nursing devices, exploring the application of brain-computer interfaces in patient monitoring [20][40] - The company aims to utilize brain signals for real-time patient status monitoring, enhancing medical service efficiency [20][40] - As the demand for precise monitoring in medical services increases, the application of BCI in healthcare settings is expected to accelerate [20][40]

Core Insights - The AI healthcare sector experienced a rise of 1.31% on February 9, with Innovative Medical leading the gains [1] - The Shanghai Composite Index closed at 4123.09, up by 1.41%, while the Shenzhen Component Index closed at 14208.44, up by 2.17% [1] Market Flow - On the same day, the AI healthcare sector saw a net inflow of 587 million yuan from major funds, while retail investors experienced a net outflow of 105 million yuan [1] - The overall fund flow in the AI healthcare sector indicates a mixed sentiment, with major funds investing while retail investors withdrew [1]

Core Viewpoint - Innovation Medical (002173) experienced a decline in stock price, closing at 27.56 yuan on February 6, 2026, down 6.1% with a turnover rate of 13.49% and a trading volume of 561,400 hands, amounting to a total transaction value of 1.558 billion yuan [1]. Group 1: Financial Performance - For the first three quarters of 2025, Innovation Medical reported a main revenue of 597 million yuan, a year-on-year decrease of 2.11% [3]. - The net profit attributable to shareholders was 4.7244 million yuan, showing a significant year-on-year increase of 116.97% [3]. - The net profit after deducting non-recurring gains and losses was -29.4698 million yuan, with a year-on-year increase of 6.05% [3]. - In the third quarter of 2025, the company recorded a single-quarter main revenue of 196 million yuan, down 3.16% year-on-year [3]. - The single-quarter net profit attributable to shareholders was 16.0857 million yuan, reflecting a substantial year-on-year increase of 236.15% [3]. - The single-quarter net profit after deducting non-recurring gains and losses was -16.5858 million yuan, down 12.36% year-on-year [3]. - The company's debt ratio stood at 17.84%, with investment income of 29.5055 million yuan and financial expenses of 605,500 yuan, resulting in a gross profit margin of 10.08% [3]. Group 2: Capital Flow - On February 6, 2026, the net outflow of main funds was 139 million yuan, accounting for 8.92% of the total transaction value [1]. - Retail investors saw a net inflow of 134 million yuan, representing 8.62% of the total transaction value [1]. - The financing data indicated a financing buy of 91.3835 million yuan and a financing repayment of 115 million yuan, resulting in a net repayment of 23.2524 million yuan [2]. - The margin trading data showed no shares were sold or repaid, with a remaining margin of 13,700 shares and a margin balance of 377,600 yuan [2]. - The total balance of margin trading and securities lending was 542 million yuan [2].

Core Viewpoint - Innovation Medical (002173) experienced a significant decline in stock price, closing at 27.56 yuan, down 6.1% on February 6, 2026, with notable trading activity and capital flow trends observed [1][2][3] Trading Information Summary - On February 6, 2026, Innovation Medical's stock closed at 27.56 yuan, reflecting a 6.1% decrease, with a trading volume of 561,446 shares and a total transaction value of 155.8 million yuan [1][2] - Over the past 10 trading days, the main capital flow showed a cumulative net outflow of 371 million yuan, with the stock price declining by 7.76% during the same period [2][3] - On February 6, the main capital saw a net outflow of 139 million yuan, while retail investors contributed a net inflow of 134 million yuan [2][3]

证券之星消息，截至2026年2月5日收盘，创新医疗(002173)报收于29.35元，上涨0.82%，换手率 17.39%，成交量72.38万手，成交额21.02亿元。 2月5日的资金流向数据方面，主力资金净流出5376.28万元，占总成交额2.56%，游资资金净流入 2663.53万元，占总成交额1.27%，散户资金净流入2712.74万元，占总成交额1.29%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 创新医疗2025年三季报显示，前三季度公司主营收入5.97亿元，同比下降2.11%；归母净利润472.44万 元，同比上升116.97%；扣非净利润-2946.98万元，同比上升6.05%；其中2025年第三季度，公司单季度 主营收入1.96亿元，同比下降3.16%；单季度归母净利润1608.57万元，同比上升236.15%；单季度扣非 净利润-1658.58万元，同比下降12.36%；负债率17.84%，投资收益2950.55万元，财务费用60.55万元， 毛利率10.08%。创新医疗（002173）主营业务：提供医疗服务。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状 ...

Core Insights - The article highlights the significant growth in the approval of innovative medical devices in China, indicating a strong focus on innovation and regulatory support in the sector [1] Group 1: Approval Statistics - In 2025, a total of 76 innovative medical devices were approved for market entry, representing a year-on-year increase of 17%, with a cumulative total of 391 devices approved [1] - There were 25 medical devices that received priority approval for market entry, showing a remarkable year-on-year growth of 212.5%, leading to a cumulative total of 171 devices approved [1]

Core Viewpoint - The news highlights the recent surge in stock prices for Innovation Medical, Weisi Medical, and Jiachuan Video, driven by the announcement of China's first "Traditional Chinese Medicine Brain-Computer Interface" equipment being deployed, which has been tested in space on the Shenzhou series manned spacecraft [1] Group 1 - Innovation Medical's stock rose over 3% in the short term [1] - Weisi Medical and Jiachuan Video saw their stock prices increase by more than 1% [1] - The "Traditional Chinese Medicine Brain-Computer Interface" technology is now operational and has been utilized for space-based experiments [1]

创新医疗短线拉升涨超3%，伟思医疗、佳创视讯涨超1%。 ...

截至2026年1月30日收盘，创新医疗(002173)报收于28.02元，下跌2.4%，换手率8.71%，成交量36.24万 手，成交额10.14亿元。 当日关注点 交易信息汇总 资金流向 1月30日主力资金净流出1.04亿元；游资资金净流出3904.88万元；散户资金净流入1.43亿元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月30日主力资金净流出1.04亿元，散户资金净流入1.43亿元。 来自公司公告汇总：创新医疗预计2025年度净利润为-3,300万元至-2,600万元，同比亏损大幅收 窄。 公司公告汇总 2025年度业绩预告 创新医疗管理股份有限公司发布2025年度业绩预告，预计报告期内归属于上市公司股东的净利润 为-3,300万元至-2,600万元，较上年同期亏损收窄64.88%至72.33%；扣除非经常性损益后的净利润 为-7,500万元至-6,800万元，同比下降14.14%至25.89%。营业收入预计为78,000万元至80,000万元，上年 同期为81,601.88万元。业绩变动主要原 ...

Core Viewpoint - The event held in Chengdu East New Area aims to accelerate the transformation of clinical research results in innovative medical devices, marking a significant step in building a comprehensive innovation ecosystem in the Sichuan-Chongqing region [1][2]. Group 1: Event Overview - The "Spring Rain Action" clinical research results transformation docking conference was held on January 31, gathering nearly 200 guests from government, medical, academic, research, and industry sectors [1]. - The event was co-hosted by the Sichuan Provincial Drug Administration and the Chengdu East New Area Management Committee, focusing on creating a high-efficiency connection bridge for innovative medical device projects with clinical value [1]. Group 2: Policy and Project Highlights - A representative from the Sichuan Provincial Economic and Information Technology Department presented policies supporting the high-quality development of the biopharmaceutical and medical device industries [1]. - Fifteen clinical transformation projects from various top-tier hospitals in the province were showcased, covering advanced fields such as minimally invasive surgical robots, new diagnostic devices, and high-end rehabilitation equipment [1]. Group 3: Collaboration and Development - Following the presentation, project teams engaged in face-to-face discussions with relevant medical device companies, resulting in several initial cooperation intentions and the signing of intention agreements on-site [2]. - The Chengdu Future Medical City aims to create an integrated innovation development system centered on clinical medical applications, positioning itself as a hub for medical device innovation in the western region [2]. Group 4: Future Goals - The Chengdu Future Medical City plans to enhance the transformation of innovative results by leveraging its "medical education-research-industry" development system, contributing to the sustainable growth of the provincial medical device industry [3].